Apolipoprotein M-A Marker or an Active Player in Type II Diabetes?

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Apolipoprotein M-A Marker or an Active Player in Type II Diabetes? / Christoffersen, Christina.

I: Frontiers in Endocrinology, Bind 12, 665393, 2021.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Christoffersen, C 2021, 'Apolipoprotein M-A Marker or an Active Player in Type II Diabetes?', Frontiers in Endocrinology, bind 12, 665393. https://doi.org/10.3389/fendo.2021.665393

APA

Christoffersen, C. (2021). Apolipoprotein M-A Marker or an Active Player in Type II Diabetes? Frontiers in Endocrinology, 12, [665393]. https://doi.org/10.3389/fendo.2021.665393

Vancouver

Christoffersen C. Apolipoprotein M-A Marker or an Active Player in Type II Diabetes? Frontiers in Endocrinology. 2021;12. 665393. https://doi.org/10.3389/fendo.2021.665393

Author

Christoffersen, Christina. / Apolipoprotein M-A Marker or an Active Player in Type II Diabetes?. I: Frontiers in Endocrinology. 2021 ; Bind 12.

Bibtex

@article{62857f2bcd6b4de2a9f95119716e84d6,
title = "Apolipoprotein M-A Marker or an Active Player in Type II Diabetes?",
abstract = "Apolipoprotein M (apoM) is a member of the lipocalin superfamily and an important carrier of the small bioactive lipid sphingosine-1-phosphate (S1P). The apoM/S1P complex is attached to all lipoproteins, but exhibits a significant preference for high-density lipoproteins. Although apoM, S1P, and the apoM/S1P complex have been discovered more than a decade earlier, the overall function of the apoM/S1P complex remains controversial. Evidence suggests that the complex plays a role in inflammation and cholesterol metabolism and is important for maintaining a healthy endothelial barrier, regulating the turnover of triglycerides from lipoproteins, and reducing cholesterol accumulation in vessel walls. Recent studies have also addressed the role of apoM and S1P in the development of diabetes and obesity. However, limited evidence is available, and the data published so far deviates. This review discusses the specific elements indicative of the protective or harmful effects of apoM, S1P, and the apoM/S1P complex on type 2 diabetes development. Since drugs targeting the S1P system and its receptors are available and could be potentially used for treating diabetes, this research topic is a pertinent one.",
keywords = "apolipoprotein M, sphingosine-1-phosphate, obesity, diabetes, insulin resistance",
author = "Christina Christoffersen",
year = "2021",
doi = "10.3389/fendo.2021.665393",
language = "English",
volume = "12",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S.A.",

}

RIS

TY - JOUR

T1 - Apolipoprotein M-A Marker or an Active Player in Type II Diabetes?

AU - Christoffersen, Christina

PY - 2021

Y1 - 2021

N2 - Apolipoprotein M (apoM) is a member of the lipocalin superfamily and an important carrier of the small bioactive lipid sphingosine-1-phosphate (S1P). The apoM/S1P complex is attached to all lipoproteins, but exhibits a significant preference for high-density lipoproteins. Although apoM, S1P, and the apoM/S1P complex have been discovered more than a decade earlier, the overall function of the apoM/S1P complex remains controversial. Evidence suggests that the complex plays a role in inflammation and cholesterol metabolism and is important for maintaining a healthy endothelial barrier, regulating the turnover of triglycerides from lipoproteins, and reducing cholesterol accumulation in vessel walls. Recent studies have also addressed the role of apoM and S1P in the development of diabetes and obesity. However, limited evidence is available, and the data published so far deviates. This review discusses the specific elements indicative of the protective or harmful effects of apoM, S1P, and the apoM/S1P complex on type 2 diabetes development. Since drugs targeting the S1P system and its receptors are available and could be potentially used for treating diabetes, this research topic is a pertinent one.

AB - Apolipoprotein M (apoM) is a member of the lipocalin superfamily and an important carrier of the small bioactive lipid sphingosine-1-phosphate (S1P). The apoM/S1P complex is attached to all lipoproteins, but exhibits a significant preference for high-density lipoproteins. Although apoM, S1P, and the apoM/S1P complex have been discovered more than a decade earlier, the overall function of the apoM/S1P complex remains controversial. Evidence suggests that the complex plays a role in inflammation and cholesterol metabolism and is important for maintaining a healthy endothelial barrier, regulating the turnover of triglycerides from lipoproteins, and reducing cholesterol accumulation in vessel walls. Recent studies have also addressed the role of apoM and S1P in the development of diabetes and obesity. However, limited evidence is available, and the data published so far deviates. This review discusses the specific elements indicative of the protective or harmful effects of apoM, S1P, and the apoM/S1P complex on type 2 diabetes development. Since drugs targeting the S1P system and its receptors are available and could be potentially used for treating diabetes, this research topic is a pertinent one.

KW - apolipoprotein M

KW - sphingosine-1-phosphate

KW - obesity

KW - diabetes

KW - insulin resistance

U2 - 10.3389/fendo.2021.665393

DO - 10.3389/fendo.2021.665393

M3 - Review

C2 - 34093440

VL - 12

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

M1 - 665393

ER -

ID: 272070817